ATE540697T1 - Stabilisiertes synthetisches immunogen- abgabesystem - Google Patents

Stabilisiertes synthetisches immunogen- abgabesystem

Info

Publication number
ATE540697T1
ATE540697T1 AT03709134T AT03709134T ATE540697T1 AT E540697 T1 ATE540697 T1 AT E540697T1 AT 03709134 T AT03709134 T AT 03709134T AT 03709134 T AT03709134 T AT 03709134T AT E540697 T1 ATE540697 T1 AT E540697T1
Authority
AT
Austria
Prior art keywords
immunostimulatory complex
delivery system
formulated
cells
produce
Prior art date
Application number
AT03709134T
Other languages
English (en)
Inventor
Kenneth Sokoll
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Application granted granted Critical
Publication of ATE540697T1 publication Critical patent/ATE540697T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT03709134T 2002-02-14 2003-02-14 Stabilisiertes synthetisches immunogen- abgabesystem ATE540697T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/076,674 US8088388B2 (en) 2002-02-14 2002-02-14 Stabilized synthetic immunogen delivery system
PCT/US2003/004711 WO2003068169A2 (en) 2002-02-14 2003-02-14 Stabilized synthetic immunogen delivery system
US10/355,161 US8084015B2 (en) 2002-02-14 2003-05-21 Stabilized synthetic immunogen delivery system

Publications (1)

Publication Number Publication Date
ATE540697T1 true ATE540697T1 (de) 2012-01-15

Family

ID=33422414

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03709134T ATE540697T1 (de) 2002-02-14 2003-02-14 Stabilisiertes synthetisches immunogen- abgabesystem

Country Status (14)

Country Link
US (2) US8088388B2 (de)
EP (1) EP1572074B1 (de)
JP (2) JP5156170B2 (de)
CN (2) CN101001646B (de)
AT (1) ATE540697T1 (de)
AU (1) AU2003213091C1 (de)
BR (1) BRPI0307724B8 (de)
CA (1) CA2475102C (de)
DK (1) DK1572074T3 (de)
ES (1) ES2383172T3 (de)
HK (1) HK1085652A1 (de)
MX (1) MXPA04007935A (de)
TW (1) TWI359025B (de)
WO (1) WO2003068169A2 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US7637948B2 (en) 1997-10-10 2009-12-29 Senorx, Inc. Tissue marking implant
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
PT1077722E (pt) 1998-05-22 2006-12-29 Coley Pharm Group Inc Produtos e composições para utilização na indução da imunidade mucosal
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US9820824B2 (en) 1999-02-02 2017-11-21 Senorx, Inc. Deployment of polysaccharide markers for treating a site within a patent
US6725083B1 (en) 1999-02-02 2004-04-20 Senorx, Inc. Tissue site markers for in VIVO imaging
US8498693B2 (en) 1999-02-02 2013-07-30 Senorx, Inc. Intracorporeal marker and marker delivery device
US20090216118A1 (en) 2007-07-26 2009-08-27 Senorx, Inc. Polysaccharide markers
US7651505B2 (en) 2002-06-17 2010-01-26 Senorx, Inc. Plugged tip delivery for marker placement
US7983734B2 (en) 2003-05-23 2011-07-19 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US6862470B2 (en) 1999-02-02 2005-03-01 Senorx, Inc. Cavity-filling biopsy site markers
US8361082B2 (en) 1999-02-02 2013-01-29 Senorx, Inc. Marker delivery device with releasable plug
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6575991B1 (en) 1999-06-17 2003-06-10 Inrad, Inc. Apparatus for the percutaneous marking of a lesion
CA2446993C (en) 2000-11-20 2009-06-02 Senorx, Inc. Tissue site markers for in vivo imaging
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002361468A1 (en) * 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
CN100471486C (zh) * 2002-08-12 2009-03-25 戴纳伐克斯技术股份有限公司 免疫调节组合物,其制备方法和使用方法
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US20060036158A1 (en) 2003-11-17 2006-02-16 Inrad, Inc. Self-contained, self-piercing, side-expelling marking apparatus
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
US7877133B2 (en) * 2003-05-23 2011-01-25 Senorx, Inc. Marker or filler forming fluid
ES2315681T3 (es) * 2003-07-28 2009-04-01 Mallinckrodt, Inc. Composicion de estearato mejorada y metodo de produccion.
US20050273002A1 (en) 2004-06-04 2005-12-08 Goosen Ryan L Multi-mode imaging marker
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US10357328B2 (en) 2005-04-20 2019-07-23 Bard Peripheral Vascular, Inc. and Bard Shannon Limited Marking device with retractable cannula
US8052658B2 (en) 2005-10-07 2011-11-08 Bard Peripheral Vascular, Inc. Drug-eluting tissue marker
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
JP2009534309A (ja) 2006-03-31 2009-09-24 マサチューセッツ インスティテュート オブ テクノロジー 治療剤の標的化送達のためのシステム
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
EP2079385B1 (de) 2006-10-23 2013-11-20 C.R.Bard, Inc. Brustkennzeichner
US9579077B2 (en) 2006-12-12 2017-02-28 C.R. Bard, Inc. Multiple imaging mode tissue marker
WO2008076973A2 (en) 2006-12-18 2008-06-26 C.R.Bard Inc. Biopsy marker with in situ-generated imaging properties
JP2008174490A (ja) * 2007-01-18 2008-07-31 Nitto Denko Corp 抗原性ペプチドを主成分とする薬剤
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
JP2008308474A (ja) * 2007-06-18 2008-12-25 Nitto Denko Corp 抗原ペプチド製剤の調製方法
AU2008314647B2 (en) 2007-10-12 2013-03-21 Massachusetts Institute Of Technology Vaccine nanotechnology
WO2009099767A2 (en) 2008-01-31 2009-08-13 C.R. Bard, Inc. Biopsy tissue marker
DE102008024470B4 (de) * 2008-05-21 2022-10-20 Faurecia Emissions Control Technologies, Germany Gmbh Verfahren zum Regenerieren eines Abgasreinigungsfilters sowie Verdampfer
PL2310046T3 (pl) 2008-06-27 2016-09-30 Nowe kompozycje adiuwantowe
US20090005320A1 (en) * 2008-09-02 2009-01-01 Bruce Kneller Compositions comprising amino acid bicarbonate and methods of use thereof
US9327061B2 (en) 2008-09-23 2016-05-03 Senorx, Inc. Porous bioabsorbable implant
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
SG186611A1 (en) 2008-12-09 2013-01-30 Pfizer Vaccines Llc Ige ch3 peptide vaccine
EP3005971B1 (de) 2008-12-30 2023-04-26 C. R. Bard, Inc. Markerabgabevorrichtung für die anbringung von gewebemarkierungen
US8629151B2 (en) 2009-05-27 2014-01-14 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
CN103936841B (zh) * 2009-06-04 2016-01-20 中牧实业股份有限公司 一种动物用肽疫苗及其制备
WO2011097384A2 (en) * 2010-02-04 2011-08-11 Board Of Regents, The University Of Texas System Tumor targeted delivery of immunomodulators by nanoplymers
EP2540311A4 (de) 2010-02-26 2016-07-06 Univ Nagasaki Verbundkörper zur verabreichung von antigenen oder heilmitteln
EP2575773A4 (de) 2010-05-26 2014-06-25 Selecta Biosciences Inc Synthetische nanoträgerkombinationsimpfstoffe
JP5902160B2 (ja) * 2010-07-08 2016-04-13 ユナイテッド・バイオメディカル・インコーポレーテッドＵｎｉｔｅｄ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ デザイナーペプチドベースのｐｃｖ２ワクチン
US20120070459A1 (en) * 2010-09-22 2012-03-22 Goovaerts Daniel G E Method for keeping a foot-and-mouth disease vaccine available for emergency vaccination
CN102010461B (zh) * 2010-10-11 2014-02-12 华南理工大学 一种alpha螺旋状阳离子多肽分子及其制法和应用
EA201390660A1 (ru) 2010-11-05 2013-11-29 Селекта Байосайенсиз, Инк. Модифицированные никотиновые соединения и связанные способы
JP5930146B2 (ja) * 2011-03-28 2016-06-08 国立研究開発法人物質・材料研究機構 免疫刺激オリゴヌクレオチドおよび前記免疫刺激オリゴヌクレオチドを含む治療剤
CN103702687A (zh) 2011-07-29 2014-04-02 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
MX358912B (es) * 2011-12-30 2018-09-07 United Biomedical Inc Vacuna de marcadores basados en péptidos sintéticos y sistema de diagnóstico para el control efectivo del síndrome reproductivo y respiratorio porcino (prrs).
EP2919808B1 (de) * 2012-11-16 2020-07-29 United Biomedical, Inc. Auf synthetischem peptid basierter notfallimpfstoff gegen maul- und klauenseuche (mks)
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
EP3024936B1 (de) 2013-07-25 2019-09-04 Exicure, Inc. Sphärische nukleinsäurebasierte konstrukte als immunstimulatoren für prophylaktische und therapeutische verwendung
JP6586083B2 (ja) 2013-09-19 2019-10-02 ゾエティス・サービシーズ・エルエルシー 油性アジュバント
USD716451S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715442S1 (en) 2013-09-24 2014-10-14 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716450S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715942S1 (en) 2013-09-24 2014-10-21 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
CN103848902B (zh) * 2014-03-07 2016-07-13 中牧实业股份有限公司 一种合成肽疫苗及其制备方法
CA2953216C (en) 2014-06-04 2020-12-22 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US20170216418A1 (en) * 2014-07-25 2017-08-03 United Biomedical, Inc. Immunogenic lhrh composition and use thereof in pigs
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US9502964B2 (en) * 2014-12-16 2016-11-22 Intel Corporation Systems and methods for skewing DC/DC converter phases to mitigate spurs
SI3244920T1 (sl) * 2015-01-16 2023-09-29 The United States of America, represented by The Secretary of Agriculture, United States Department of Agriculture Cepivo proti slinavki in parkljevki
KR102656644B1 (ko) * 2015-02-09 2024-04-09 슬링샷 바이오사이언시즈 인코포레이티드 튜닝가능한 광 특성을 갖는 하이드로겔 입자 및 이를 사용하기 위한 방법
JP6975132B2 (ja) * 2015-07-20 2021-12-01 ゾエティス・サービシーズ・エルエルシー リポソームアジュバント組成物
WO2017043490A1 (ja) * 2015-09-07 2017-03-16 協和発酵バイオ株式会社 自然免疫誘導効果が増強した二重鎖リボ核酸
AU2017274332B2 (en) 2016-06-02 2024-06-27 Zoetis Services Llc Vaccine against infectious bronchitis
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
CN107703294B (zh) * 2017-10-12 2019-06-04 华派生物工程集团有限公司 一种用于检测鸡血清中cLHRH抗体效价的ELISA方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5135751A (en) * 1988-11-16 1992-08-04 Mediventures Incorporated Composition for reducing postsurgical adhesions
US5126141A (en) * 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
GB8921470D0 (en) 1989-09-22 1989-11-08 Peptide Technology Ltd Vaccines
DE59107006D1 (de) * 1990-04-25 1996-01-18 Hoechst Ag Pharmakologische Zubereitung, enthaltend Polyelektrolytkomplexe in mikropartikulärer Form und mindestens einen Wirkstoff.
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
AU659482B2 (en) 1991-06-28 1995-05-18 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
ES2180576T3 (es) * 1993-04-27 2003-02-16 United Biomedical Inc Construcciones peptidicas de lhrh inmunogenicas y estimuladores de inmunidad universales sinteticos para vacunas.
US5562909A (en) * 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK0772619T4 (da) * 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US6042820A (en) * 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2301587C (en) * 1997-08-29 2008-07-08 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
AU1384199A (en) * 1997-11-07 1999-05-31 Chiron Corporation Method for producing igf-1 sustained-release formulations
JP2002511423A (ja) 1998-04-09 2002-04-16 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
JP2002518033A (ja) 1998-06-20 2002-06-25 ユナイティド バイオメディカル インコーポレイティド 農場動物の成長促進のための合成ソマトスタチン免疫原
US6107021A (en) * 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
JP2002537102A (ja) * 1999-02-26 2002-11-05 カイロン コーポレイション 吸着された高分子および微粒子を有するミクロエマルジョン
OA12028A (en) * 1999-09-25 2006-04-28 Univ Iowa Res Found Immunostimulatory nucleic acids.
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
SK287689B6 (sk) * 2000-06-08 2011-06-06 Intercell Ag Použitie molekuly oligodeoxynukleovej kyseliny na výrobu imunostimulačnej farmaceutickej kompozície a farmaceutický prípravok
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
ATE440618T1 (de) 2000-06-22 2009-09-15 Univ Iowa Res Found Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.
WO2002053141A2 (en) * 2000-12-14 2002-07-11 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US6780969B2 (en) * 2000-12-22 2004-08-24 United Biomedical, Inc. Synthetic peptide composition as immunogens for prevention of urinary tract infection
US20040185055A1 (en) * 2001-03-19 2004-09-23 Glenn Gregory M Transcutaneous immunostimulation
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
WO2005009462A2 (en) * 2003-07-24 2005-02-03 Merial Limited Vaccine formulations comprising an oil-in-water emulsion

Also Published As

Publication number Publication date
AU2003213091B2 (en) 2008-06-05
US20040009897A1 (en) 2004-01-15
JP5156170B2 (ja) 2013-03-06
AU2003213091A1 (en) 2003-09-04
MXPA04007935A (es) 2005-06-08
TWI359025B (en) 2012-03-01
DK1572074T3 (da) 2012-05-07
EP1572074A4 (de) 2008-04-30
US8088388B2 (en) 2012-01-03
US8084015B2 (en) 2011-12-27
US20030165478A1 (en) 2003-09-04
BR0307724A (pt) 2007-04-27
JP5237997B2 (ja) 2013-07-17
CN101001646A (zh) 2007-07-18
TW200307557A (en) 2003-12-16
BRPI0307724B8 (pt) 2021-05-25
WO2003068169A2 (en) 2003-08-21
JP2005530690A (ja) 2005-10-13
CN101001646B (zh) 2014-01-01
ES2383172T3 (es) 2012-06-18
CA2475102A1 (en) 2003-08-21
AU2003213091C1 (en) 2009-01-08
HK1085652A1 (en) 2006-09-01
CA2475102C (en) 2013-04-23
EP1572074B1 (de) 2012-01-11
JP2010265291A (ja) 2010-11-25
BRPI0307724B1 (pt) 2019-06-18
EP1572074A2 (de) 2005-09-14
WO2003068169A3 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
DK1572074T3 (da) Stabiliseret syntetisk immunogen-afgivelsessystem
TR200100936T2 (tr) Terapötik aşılama
MY125202A (en) Vaccine
PL351893A1 (en) Vaccines
ATE315405T1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
EP1546206A4 (de) Neue immunogene lipopeptide, die t-helfer- und cytotoxic-t-lymphocyte-(clt-)epitope enthalten
NZ542138A (en) Heterobifunctional polymeric bioconjugates
GB0025577D0 (en) Vaccine
ATE371668T1 (de) Antigene aus chlamydia trachomatis
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
ATE270707T1 (de) Entepneumovirus und entsprechendes impfstoff
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
ATE416788T1 (de) Verwendung von pflanzen-öl-körper in impfstoffverabreichungsysteme
WO2004005325A3 (en) Antigen-polymer compositions
ATE310008T1 (de) Immunologische adjuvans verbindungen
BR0112258A (pt) Sistema de entrega de droga para drogas pouco solúveis em água
MXPA03010261A (es) Metodos para tratar cancer.
WO2000012122A3 (de) Niedermolekulare fragmente der hyaluronsäure zur herstellung von impfstoffen
ITVA20020023A1 (it) Prodotti per l'edilizia a base di idrossialchilguaro purificato
SE9903534D0 (sv) Vaccin
EP1035133A3 (de) Fusionsproteine mit Trägern welche eine doppelte Immunantwort induzieren
MY127452A (en) Vaccines.
EP1667634A4 (de) Anthrax-vakzine
CO5280140A1 (es) Antigeno (c42) asociado a tumores